You are here

Article Text

Article menu
Download PDFPDF
Laboratory science - Scientific reports
Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin)
  1. Roberta P A Manzano1,2,
  2. Gholam A Peyman1,
  3. Palwasha Khan1,
  4. Petros E Carvounis1,
  5. Muhamet Kivilcim3,
  6. Min Ren1,
  7. Jonathan C Lake2,
  8. Patricia Chévez-Barrios1
  1. 1Department of Ophthalmology, Tulane University Health Sciences Center, New Orleans, Louisiana, USA
  2. 2Department of Ophthalmology, Santa Casa de Misericórdia de São Paulo, São Paulo, Brazil
  3. 3Department of Ophthalmology, University of Arizona, Arizona Health Sciences Center, Tucson, Arizona, USA
  1. Correspondence to: Dr G A Peyman Department of Ophthalmology, University of Arizona, 655 N Alvernon Way, Ste 108, Tucson, AZ 85711, USA; ccole{at}eyes.arizona.edu

Abstract

Aim: To evaluate the effect of topically administered bevacizumab (Avastin) on experimental corneal neovascularisation in rats.

Methods: Silver nitrate sticks (75% silver nitrate, 25% potassium nitrate) were used to perform chemical cauterisation on the corneas of 16 eyes from 16 male Long Evans rats. For the following 7 days, the 10 eyes in the treatment group were instilled with bevacizumab 4 mg/ml drops twice daily, whereas the 6 eyes in the control group received placebo (normal saline drops twice daily). Digital photographs of the cornea were analysed to determine the area of cornea covered by neovascularisation as a percentage of the total corneal area.

Results: In the bevacizumab-treated eyes, neovascularisation covered, on average, 38.2% (15.5%) (mean (SD)) of the corneal surface compared with 63.5% (5.0%) in the control group (p<0.02, Mann–Whitney U test).

Conclusion: Topically administered bevacizumab (Avastin) at a concentration of 4 mg/ml limits corneal neovascularisation following chemical injury in the male Long Evans rat model.

  • VEGF, vascular endothelial growth factor

https://doi.org/10.1136/bjo.2006.107912

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Published Online First 19 December 2006

    • Competing interests: None.

    Linked Articles

    • BJO at a glance
      BJO at a glance
      Creig Hoyt
      British Journal of Ophthalmology 2007; 91 705-705 Published Online First: 17 May 2007.